Can a new Lyme disease vaccine overcome a history of distrust and failure?
As the threat of Lyme disease grows and fears surrounding it spread faster than the ticks that carry the infection, researchers are developing two vaccine or vaccine-like approaches to prevent this increasingly problematic disease. But don’t expect to get one soon. They are at least three to five years away from clinical use, according to their developers.
That may seem like a long time to wait, especially since there are several Lyme disease vaccines available for dogs. But it’s taken researchers almost two decades to get this close — for the second time. Developers have faced an uphill battle since LYMErix, a short-lived human vaccine, was pulled from the market in 2002 amid low demand and lawsuits over potential side effects, not to mention mounting distrust in vaccines.
“There was a huge dampening of enthusiasm after LYMErix failed,” said Sam Telford, professor of vector-borne infections and public health at Tufts University, who helped run the LYMErix clinical trial. “Companies said, ‘Look, we just don’t want to go there.’ There was a lot of negativity around making a new Lyme disease vaccine.”
As work moves forward on these two new approaches, here’s the question on many minds: Is the market ready for a new Lyme disease vaccine?
A closer look at the new products
One of the new approaches is a vaccine, which works by stimulating the immune system to make antibodies that can attack Borrelia burgdorferi and other types of Borrelia, the bacteria that cause Lyme disease. The other is an injection of a single antibody.
You’re reading a preview, subscribe to read more.
Start your free 30 days